Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Imlygic patent expiry united kingdom?

See the DrugPatentWatch profile for Imlygic

When does the Imlygic (talimogene laherparepvec, T-VEC) patent expire in the UK?

The exact UK patent expiry date for Imlygic depends on which specific patent(s) protect the product in the United Kingdom (for example, patents covering the active substance, formulation, method of treatment, or specific genetic modifications). Different patents expire on different dates, so “the” expiry date varies by patent family and by whether any supplementary protections apply.

The information provided here does not include the relevant UK patent numbers or their recorded expiry dates, so I can’t state a specific UK date reliably from the supplied data.

How can you find the correct UK expiry date for Imlygic?

To get the precise expiry, you typically need to:
- Identify the key UK patent family members for Imlygic (UK publication/patent numbers).
- Check each patent’s scheduled end date in the UK patent register (and any evidence of earlier expiry, changes, or ongoing proceedings).
- If present, check whether supplementary protection (such as SPC-related protection, where applicable) extends protection beyond the basic patent expiry.

Does the UK have additional exclusivity beyond patents?

In the UK, exclusivity can come from patent rights plus other regulatory or exclusivity mechanisms. For medicines like Imlygic, the overall time window for generic or biosimilar-style competition is often determined by the last-to-expire relevant protection (not a single headline date). Without the specific UK patent/SPC identifiers, the timeline can’t be pinned down.

What’s the practical meaning of “patent expiry” for Imlygic in the UK?

Even after a particular patent expires, competitors may still be blocked by:
- Other unexpired patents in the same family or other families.
- Patents that cover different aspects (e.g., treatment regimen, vector design, or manufacturing).
- Ongoing litigation or injunctions tied to specific claims.

So competitors may wait until the last relevant UK protection expires, not just the first one.

If you share a detail, I can give a specific date

If you provide any of the following, I can help translate it into the likely UK expiry timeline:
- UK patent number(s) for Imlygic you’re looking at
- A link or screenshot to the UK patent entry
- The patent family/publication number (e.g., “EP…”, “WO…”) you want mapped to the UK

Sources

No sources were provided in the prompt.



Other Questions About Imlygic :

Imlygic amgen? Imlygic sales 2024? Imlygic? Imlygic sales? Imlygic cost?

AI-Drug Label Prescribing Information Alignment Report

No report available.

Drug Brand Mention Assessment

Branding Score
46
Visibility
45
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

Imlygic (talimogene laherparepvec, T-VEC) patent expiry in the UK


Core Claims
  • The exact UK patent expiry date depends on which specific patent(s) protect Imlygic in the UK.
  • Different patents expire on different dates, so the expiry date varies by patent family and supplementary protections.
  • The response cannot state a specific UK expiry date reliably from the supplied data.
  • In the UK, exclusivity beyond patents can come from other regulatory or exclusivity mechanisms.
  • Even after a particular patent expires, competitors may still be blocked by other unexpired patents, ongoing litigation, or injunctions.
Differentiators
  • Expiry is described as depending on last-to-expire relevant protection rather than a single headline date.
  • The response emphasizes mapping specific UK patent/SPC identifiers to determine the timeline.

Pricing Perception: Not Mentioned